LUMATEPERONE TOSYLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUMATEPERONE TOSYLATE (LUMATEPERONE TOSYLATE).
Lumateperone tosylate is an atypical antipsychotic with a unique mechanism of action involving antagonism of serotonin 5-HT2A receptors, partial agonism of serotonin 5-HT1A receptors, and antagonism of dopamine D2 receptors; it also modulates glutamate via phosphorylation of GluN2B subunits and inhibits serotonin reuptake.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6; minor contributions from CYP1A2, CYP2C19, and CYP2C9. |
| Excretion | Approximately 60% excreted in urine as metabolites (unchanged drug negligible) and 30% in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 24-29 hours, allowing once-daily dosing. Steady-state reached in about 5 days. |
| Protein binding | Approximately 99% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 4-6 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 20-30% due to first-pass metabolism; increased by 2-fold with high-fat meal. |
| Onset of Action | Oral: Clinical onset of antipsychotic effect occurs within 1-2 weeks of initiating therapy. |
| Duration of Action | Duration of action supports once-daily dosing due to long half-life. Clinical effect persists with regular administration. |
| Molecular Weight | 492.6 |
| Action Class | Atypical Antipsychotic |
42 mg orally once daily
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce to 21 mg once daily; Child-Pugh Class C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment; use with caution due to increased risk of adverse effects (e.g., hypotension, sedation). |
| 1st trimester | Limited human data; in animal studies, no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded. |
| 2nd trimester | Limited human data; consider risk-benefit. No known specific malformations. |
| 3rd trimester | Use in third trimester may cause extrapyramidal and/or withdrawal symptoms in neonates (e.g., agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress). Monitor neonate. |
Clinical note
Comprehensive clinical and safety monograph for LUMATEPERONE TOSYLATE (LUMATEPERONE TOSYLATE).
| Placental transfer | Likely crosses placenta due to molecular weight (<1000 Da); no specific human data on transfer rate. |
| Breastfeeding | Excreted in animal milk; unclear if in human milk. Consider benefits of breastfeeding, risks of infant exposure, and importance of drug to mother. Monitor infant for sedation, poor feeding. |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; lumateperone is not approved for the treatment of dementia-related psychosis.
| Common Effects | Somnolence/sedation, Dry mouth, Fatigue, Nausea, Dizziness, Increased appetite, Weight gain |
| Serious Effects | Cerebrovascular adverse events (including stroke) in elderly patients with dementia-related psychosis, Neuroleptic malignant syndrome (NMS), Tardive dyskinesia, Metabolic changes (hyperglycemia, diabetes mellitus, dyslipidemia, weight gain), Leukopenia, neutropenia, and agranulocytosis, Orthostatic hypotension and syncope, Seizures, Increased mortality in elderly patients with dementia-related psychosis |
Hypersensitivity to lumateperone or any component
| Precautions | Cerebrovascular adverse events in elderly patients with dementia; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); leukopenia/neutropenia; orthostatic hypotension; seizures; body temperature dysregulation; dysphagia; cognitive/motor impairment; and interactions with strong CYP3A4 inhibitors/inducers. |
Loading safety data…
| Lactation Rating | L4 (Limited data - potentially hazardous) |
| Teratogenic Risk | Pregnancy category N. Limited human data; animal studies show no teratogenicity at clinically relevant doses, but fetal toxicity (reduced weight, delayed ossification) occurred at multiples of MRHD. Avoid in first trimester unless benefit outweighs risk; use in third trimester may cause extrapyramidal symptoms or withdrawal in neonates. |
| Fetal Monitoring | Monitor maternal weight, glucose, lipids, and prolactin at baseline and periodically. Assess for extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome. Fetal monitoring: ultrasound for growth restriction if exposure in third trimester; neonatal monitoring for extrapyramidal symptoms, respiratory depression, feeding difficulties, and sedation after delivery. |
| Fertility Effects | Hyperprolactinemia may occur, potentially impairing fertility via suppression of GnRH and gonadal steroidogenesis. In males: decreased libido, erectile dysfunction, gynecomastia. In females: menstrual irregularities, amenorrhea. Reversible upon dose reduction or discontinuation. |
| Food/Dietary | Administration with food increases lumateperone absorption. Avoid grapefruit and grapefruit juice, as they may increase drug levels. No other specific food interactions identified. |
| Clinical Pearls | Lumateperone tosylate is a novel antipsychotic with a unique mechanism of action involving serotonergic, dopaminergic, and glutamatergic modulation. It does not require dose titration; the recommended dose is 42 mg once daily with food. Caution in patients with hepatic impairment: not recommended for moderate or severe impairment (Child-Pugh B or C). Monitor for somnolence/sedation, extrapyramidal symptoms, and metabolic changes. Avoid use with strong CYP3A4 inhibitors or inducers. May prolong QT interval; use with caution in patients with risk factors for QT prolongation. |
| Patient Advice | Take lumateperone exactly as prescribed, once daily with food to enhance absorption. · Do not stop taking this medication abruptly; consult your healthcare provider before discontinuing. · Avoid driving or operating heavy machinery until you know how this drug affects you, as it may cause drowsiness or dizziness. · Inform your doctor about all medications you are taking, including over-the-counter drugs and herbal supplements, to avoid interactions. · Seek immediate medical attention if you experience symptoms of an allergic reaction (rash, hives, swelling, trouble breathing) or signs of neuroleptic malignant syndrome (fever, muscle rigidity, confusion). |